Physician profile
William Hart
NPI 1851334270
$1,614.98
in general payments reported to CMS, 2019-2025
12 companies · $327 in 2025
The $327 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $275 · 2020: $35.43 · 2021: $363 · 2022: $252 · 2023: $243 · 2024: $119 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $689.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $689.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $562.76 | 2019-2025 | Idosetr, Idose |
| Alcon Vision LLC | $417.43 | 2019-2025 | Clareon |
| Abbvie INC. | $147.14 | 2023-2024 | |
| Carl Zeiss Meditec USA, INC. | $125.63 | 2022 | |
| Bausch & Lomb Americas INC. | $110.10 | 2023 | Miebo |
| Allergan, INC. | $45.46 | 2021 | |
| Sight Sciences, INC. | $45.14 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $36.91 | 2019 | |
| Sun Pharmaceutical Industries INC. | $35.80 | 2019 | |
| Aerie Pharmaceuticals, INC. | $35.32 | 2019-2020 | |
| Dompe US, INC. | $31.21 | 2025 | Oxervate |
| Biotissue Holdings INC. | $22.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Hart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.